CCR2 and melanoma: Since the advent of checkpoint inhibition, preclinical studies demonstrated that combining checkpoint blockade with CCL2/CCR2 inhibition improved responses over checkpoint blockade alone treatment in murine models of melanoma.91 The improved efficacy of this approach may be due to simultaneous targeting of both the lymphoid and myeloid compartments of the TME.